This topic contains a solution. Click here to go to the answer

Author Question: Patients receiving heparin therapy require monitoring of: 1. Platelets every 2 to 3 days for ... (Read 68 times)

B

  • Hero Member
  • *****
  • Posts: 570
Patients receiving heparin therapy require monitoring of:
 
  1. Platelets every 2 to 3 days for thrombocytopenia that may occur on day 4 of therapy
  2. Electrolytes for elevated potassium levels in the first 24 hours of therapy
  3. INR throughout therapy to stay within the range of 2.0
  4. Blood pressure for hypertension that may occur in the first 2 days of treatment

Question 2

For patients taking warfarin, INRs are best drawn:
 
  1. Monthly throughout therapy
  2. Three times a week throughout therapy
  3. Two hours after the last dose of warfarin to get an accurate peak level
  4. In the morning if the patient takes their warfarin at night



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

duy1981999

  • Sr. Member
  • ****
  • Posts: 341
Answer to Question 1

1

Answer to Question 2

4




B

  • Member
  • Posts: 570
Reply 2 on: Jul 24, 2018
:D TYSM


EAN94

  • Member
  • Posts: 307
Reply 3 on: Yesterday
Gracias!

 

Did you know?

Though newer “smart” infusion pumps are increasingly becoming more sophisticated, they cannot prevent all programming and administration errors. Health care professionals that use smart infusion pumps must still practice the rights of medication administration and have other professionals double-check all high-risk infusions.

Did you know?

Everyone has one nostril that is larger than the other.

Did you know?

About one in five American adults and teenagers have had a genital herpes infection—and most of them don't know it. People with genital herpes have at least twice the risk of becoming infected with HIV if exposed to it than those people who do not have genital herpes.

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

Did you know?

The U.S. Pharmacopeia Medication Errors Reporting Program states that approximately 50% of all medication errors involve insulin.

For a complete list of videos, visit our video library